-- 加拿大皇家銀行資本市場(RBC Capital Markets)表示,儘管中東局勢持續不明朗,但3月份符合市場預期的就業報告以及本週國內其他數據較為清淡的形勢,幫助加拿大政府債券收益率本週收盤價與上週基本持平。 RBC在周五發布的《加元週報》(CAD Weekly Sounds)中指出,由於下週數據寥寥,且今天上午公佈的美加數據不太可能對美聯儲和加拿大央行的政策走向產生重大影響,美元/加元的短期走勢可能取決於市場預期局勢升級(美元走強)還是緩和(美元走弱)。 利率展望 關於加拿大央行,RBC表示,央行已明確表示,應對近期油價飆升以及伊朗衝突帶來的連鎖反應,起點至關重要。特別是,核心通膨率正朝著目標穩步邁進,且加拿大經濟存在一定的閒置產能,這為加拿大央行評估任何潛在的次生影響提供了時間。 加拿大皇家銀行(RBC)表示,近期薪資成長的上升似乎更多是由於結構性變化所致,加拿大央行(BoC)應予以忽略。 RBC也表示,預計加拿大央行2026年利率政策將維持不變,升息將於2027年開始。 關於利差,RBC指出,儘管市場波動持續,但加美利差在中期內仍將保持橫盤整理,其中10年期國債利差本週略微負值,為-86個基點。 從技術面來看,RBC的喬治戴維斯表示,加幣10年期公債殖利率的上升趨勢在3月31日結束,此前該殖利率一度下跌至3.50%以下。這預示著收益率將首先下探至3.36%,並在3.25%附近遇到阻力。初步支撐位在3.53%,若要觸發新的下跌階段,則需回升至3.62%以上。 值得關注的關鍵事項 加拿大皇家銀行(RBC)表示,週一將舉行三場聯邦補選,其中兩場在多倫多這兩個傳統的自由黨票倉舉行。在此之前,保守黨議員倒戈加入執政的自由黨,使得自由黨在議會中以171比169的席位優勢領先,這意味著如果贏得兩場補選,自由黨將獲得明顯的多數席位,儘管優勢並不明顯。 RBC也表示,下週將公佈大量次要經濟數據,包括週三公佈的2月份製造業銷售數據、週三公佈的2月份批發貿易數據、週四公佈的3月份成屋銷售數據以及週五公佈的3月份新屋開工數據。 在全球範圍內,RBC表示,關注的焦點是與伊朗衝突相關的新聞。具體數據方面,週二將公佈美國3月生產者物價指數(PPI),週三將公佈澳洲3月份就業數據、週三將公佈中國第一季GDP及3月經濟活動指標,週四將公佈英國2月月度GDP。
Related Articles
Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
ASX Biggest Losers
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.